Table 1.
Characteristics of Mvomero study population with complete case serology data (N = 691)
| Survey 1 (2011) | Survey 2 (2012) | Survey 3 (2013) | |
|---|---|---|---|
| Age in years (N%) | |||
| <2 | 145 (21.0%) | 101 (14.6%) | 30 (4.3%) |
| 2–5 | 149 (21.6%) | 166 (24.0%) | 173 (25.0%) |
| 5–10 | 129 (18.7%) | 134 (19.4%) | 173 (25.0%) |
| 10–15 | 31 (4.5%) | 53 (7.7%) | 74 (10.7%) |
| 15–20 | 18 (2.6%) | 14 (2.0%) | 18 (2.6%) |
| 20–30 | 88 (12.7%) | 82 (11.9%) | 69 (10.0%) |
| 30–40 | 81 (11.7%) | 79 (11.4%) | 81 (11.7%) |
| 40+ | 50 (7.2%) | 62 (9.0%) | 73 (10.6%) |
| Gender | |||
| Male | 272 (39.4%) | ||
| Female | 419 (60.6%) | ||
| Malaria infections | |||
| N (%) | 34 (5.0%) | 47 (6.8%) | 95 (14.2%) |
| Seropositive (AMA-1) | |||
| N (%) | 313 (45.4%) | 249 (36.4%) | 302 (43.9%) |
| Seropositive (MSP-1) | |||
| N (%) | 227 (33.0%) | 192 (27.9%) | 278 (40.2%) |
| Number of seroconversion events (AMA-1) | n/a | ||
| N (% of seronegative in previous survey) | 19 (5.0%) | 73 (19.7%) | |
| Number of seroconversion events (MSP-1) | |||
| N (% of seronegative in previous survey) | 42 (9.1%) | 110 (22.0%) | |
| Number of seroreversion events (AMA-1) | |||
| N (% of seropositive in previous survey) | 81 (25.9%) | 21 (8.4%) | |
| Number of seroreversion events (MSP-1) | |||
| N (% of seropositive in previous survey) | 77 (33.9%) | 26 (13.5%) | |